OMX Europe Venture Fund
We believe the 21st century will be biology-driven, more than ever, where the promise of precision medicine and a biology-led industrial revolution hinges on the ability to reduce the complex interconnections of large, multi-omic data sets into useful biological information, services and products. We believe that this will ultimately lead to a sizeable market opportunity, better and cost-effective healthcare, while also addressing large social challenges such as a sustainable food supply chain.
OMX Europe Venture Fund* is a life science venture fund managed by Mérieux Equity Partners with the co-sponsorship of Korys (www.korys.be) and Mérieux Développement (www.merieux-partners.com). Korys acts as a key advisor to the fund. The Fund, through its direct link with Korys, brings together decades of expertise of investing and supporting entrepreneurship in the life science and nutrition sectors. The Fund’s strategy is to invest in highly innovative companies and best-in-class platforms at pre-commercial or commercial stage in Western Europe and North America.
Omics [ō-miks]: Refers to a field of study in biology ending in -omics (such as genomics, proteomics, metabolomics, microbiomics, etc.) in a cell, organ, or organism.
* This is not a marketing communication in the European Union member states or non-member states. This is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of securities made in the United States will be made by means of a prospectus that may be obtained from the issuer and will contain detailed information about the company and management, as well as financial statements.